Plenary Session - inactive due to federal service
A podcast on medicine, oncology, & health policy.
Host: Vinay Prasad, MD MPH from University of California, San Francisco.
Tweet your feedback to @Plenary_Session or e-mail [email protected].
- Update frequency
- every 6 days
- Average duration
- 64 minutes
- Episodes
- 397
- Years Active
- 2018 - 2025
1.36 Generic Price Competition & Military Surgical Advances with Dr. Martin Schreiber
This week we dive into the recent paper by Drs. Cole and Dusetzina titled "Generic Price Competition For Specialty Drugs: Too Little, Too Late?". We also have an interview with Dr. Martin Schreiber o…
01:16:18 |
Tue 15 Jan 2019
1.35 BONUS! Conflict of Interest in Oncology
This BONUS episode is the recording of a lecture given to the Bioethics Study Group at OHSU on January 9, 2019 on conflict of interest, specifically in the field of oncology. Backers of our Patreon w…
00:45:51 |
Thu 10 Jan 2019
1.34 Endpoints in ECOG-ACRIN 2511, Update to KEYNOTE-024, & Mentorship with Dr. Joseph Shatzel
In this episode, we discuss two recent papers published in the Journal of Clinical Oncology: ECOG-ACRIN 2511 and the update adding overall-survival and crossover results to KEYNOTE-024. We end with a…
01:10:47 |
Thu 10 Jan 2019
1.33 Guarantee-Time Bias & Trials, Philanthropy, and Cancer Research with Dr. Tom Beer
In this episode we discuss guarantee-time bias in the context of the recent JAMA Oncology paper titled "Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Sm…
01:32:12 |
Sat 05 Jan 2019
1.32.1 Radiation Oncology with Dr. Brian Kavanagh
Episode 1.32 ran a little long, so this is episode 1.32.1 - we broke out the interview with Dr. Brian Kavanagh, the Chairman of Radiation Oncology at the University of Colorado, to make the interview…
01:11:04 |
Fri 04 Jan 2019
1.32 Rating Metrics, Conflict of Interest in the News, & Radiation Oncology with Dr. Brian Kavanagh
This week we discuss various academic indices including the h-index and the new Altmetric score, and we go over the recent NY Times article on conflict of interest. We end with an interview with Dr. …
01:59:35 |
Thu 03 Jan 2019
1.31 Ketogenic Diet, COMET-1 and COMET-2, the Health Insurance Marketplace with Dr. Jane Zhu
We begin this episode with a discussion of Dr. Mukherjee's ongoing study combining a ketogenic diet with PI3 kinase inhibition. We continue with a take on a recent reanalysis of COMET-1 and COMET-2, …
01:35:03 |
Thu 27 Dec 2018
1.30 BONUS! Clinical Trial Endpoints, Drug Approval, Incentives in Oncology
This BONUS episode is the recording of a lecture given to the National Breast Cancer Coalition on December 11, 2018. It's on clinical trial endpoints, FDA drug approval, and incentives in oncology. B…
01:10:06 |
Wed 19 Dec 2018
1.29 RCT of Parachutes and Frameworks for Internal Medicine with Dr. Andre Mansoor
We begin this episode with a critique of the recent paper in the BMJ, "Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial" and we end it with an i…
01:17:47 |
Tue 18 Dec 2018
1.28 Questionable FDA Drug Approvals and Building a Career with Dr. Chadi Nabhan
In this episode we critique two recent FDA drug approvals (venetoclax in combination with azacitidine or decitabine or low-dose cytarabine; glasdegib in combination with low-dose cytarabine -- both f…
01:04:45 |
Thu 13 Dec 2018
1.27 BONUS! Medical Reversal
This BONUS episode is the recording of a lecture given to hospitalists at Kaiser Permanente on November 14, 2018. It's a slightly different version of the talk on medical reversals that we recorded f…
00:57:46 |
Thu 06 Dec 2018
1.26 Lesson From an ASH Abstract, Behind the Scenes of a Residency Program with Dr. Sima Desai
Having just returned from the 2018 American Society of Hematology (ASH) Annual Meeting, we begin this episode by discussing the abstract of a study that stretches its conclusions. We dedicate most of…
01:14:10 |
Tue 04 Dec 2018
1.25 Welch's Legacy, Interpreting NGS, Uncertainty over Pregabalin, Beyond EBM with Dr. Sam Edwards
In this episode we discuss: Dr. Gilbert Welch's Wikipedia page and how we should keep his decades of work in perspective, a Twitter conversation between experts on differing interpretations of result…
01:20:41 |
Tue 27 Nov 2018
1.24 Useless Medical Conferences and Dr. Adam Obley on Vascepa, Fish Oil, Vitamin D and Methotrexate
In this episode we discuss John Ioannidis' article on the uselessness of medical conferences, published in JAMA: "Are Medical Conferences Useful? And for Whom?", followed by an interview with return-…
00:50:18 |
Tue 20 Nov 2018
1.23 BONUS! Developing Technology with Fewer Reversals: Maybe We Need More Translation Failure
This BONUS episode is the recording of a lecture given as part of the Biomedical Engineering Seminar series at Oregon Health & Science University on November 9, 2018. The talk is on how to move techn…
01:00:10 |
Thu 15 Nov 2018
1.22 Elo-Pom-Dex, Immunotherapy Combos, Inherent Bias, and the FDA with Dr. Erick Turner
In this episode, we tackle the recent papers in the New England Journal of Medicine on "Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma" and "Immunotherapy Combinations in Multipl…
01:16:00 |
Tue 13 Nov 2018
1.21 Nab-Paclitaxel in CCA, OS of PALOMA-3, Transparency, and Dr. Talal Hilal's Advice for Trainees
In this episode we question the conclusions of the phase II trial "Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma", review the long-term overall s…
01:12:41 |
Tue 06 Nov 2018
1.20 Precision Oncology: Some Benefit, Mostly Hype and Mentorship with Dr. Andrae Vandross
We begin this episode analyzing the unrepentant hype of precision oncology in a monologue that was originally one half of a debate titled: "Is Precision Oncology Generating Patient Benefit or Just Hy…
01:36:58 |
Tue 30 Oct 2018
1.19 BONUS! Introduction to Cancer Drug Policy
This BONUS episode is the recording of a lecture given as part of a Cancer Intersession course for med students at Oregon Health & Science University on October 25, 2018. The talk is an introduction …
00:49:39 |
Fri 26 Oct 2018
1.18 IMpassion130 and Hot-Spotting with Dr. Brian Chan
In this episode we evaluate the IMpassion130 trial on the use of atezolizumab in triple-negative breast cancer. We also interview Dr. Brian Chan of OHSU on a randomized controlled trial he's running …
01:02:31 |
Tue 23 Oct 2018
Disclaimer: The podcast and artwork embedded on this page are the property of Vinay Prasad, MD MPH ([email protected]). This content is not affiliated with or endorsed by eachpod.com.